Altimmune, Inc.
ALT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1 | $1 | $1 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $1 | $0 |
| Revenue | $0 | $0 | -$0 | $0 |
| % Growth | -95.3% | 726.5% | -101.5% | – |
| Gross Profit | $0 | $0 | -$0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -474,060% | -20,642% | 124,130.9% | -2,189% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -475,295% | -20,762.2% | 124,577.9% | -2,201.6% |
| EPS Diluted | -1.34 | -1.66 | -1.81 | -2.35 |
| % Growth | 19.3% | 8.3% | 23% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |